Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance.
Iannelli F, Zotti AI, Roca MS, Grumetti L, Lombardi R, Moccia T, Vitagliano C, Milone MR, Ciardiello C, Bruzzese F, Leone A, Cavalcanti E, De Cecio R, Iachetta G, Valiante S, Ionna F, Caponigro F, Di Gennaro E, Budillon A. Iannelli F, et al. Among authors: de cecio r. Front Cell Dev Biol. 2020 Aug 17;8:732. doi: 10.3389/fcell.2020.00732. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33015030 Free PMC article.
Hyalinizing clear cell carcinoma of the parotid gland: report of a recurrent case with aggressive cytomorphology and behavior diagnosed on fine-needle cytology sample.
Fulciniti F, Pia Curcio M, Liguori G, Aquino G, Botti G, Campanile AC, De Cecio R, Pavone E, Aversa C, Perri F, Caponigro F, Ionna F. Fulciniti F, et al. Among authors: de cecio r. Diagn Cytopathol. 2014 Jan;42(1):63-8. doi: 10.1002/dc.22956. Epub 2013 Jul 27. Diagn Cytopathol. 2014. PMID: 23894005
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F, Di Gennaro E, Ionna F, Longo F, Aversa C, Pavone E, Maglione MG, Di Marzo M, Muto P, Cavalcanti E, Petrillo A, Sandomenico F, Maiolino P, D'Aniello R, Botti G, De Cecio R, Losito NS, Scala S, Trotta A, Zotti AI, Bruzzese F, Daponte A, Calogero E, Montano M, Pontone M, De Feo G, Perri F, Budillon A. Caponigro F, et al. Among authors: de cecio r, de feo g. BMC Cancer. 2016 Nov 25;16(1):918. doi: 10.1186/s12885-016-2957-y. BMC Cancer. 2016. PMID: 27884140 Free PMC article. Clinical Trial.
Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation.
Ciardiello C, Leone A, Lanuti P, Roca MS, Moccia T, Minciacchi VR, Minopoli M, Gigantino V, De Cecio R, Rippa M, Petti L, Capone F, Vitagliano C, Milone MR, Pucci B, Lombardi R, Iannelli F, Di Gennaro E, Bruzzese F, Marchisio M, Carriero MV, Di Vizio D, Budillon A. Ciardiello C, et al. Among authors: de cecio r. J Exp Clin Cancer Res. 2019 Jul 18;38(1):317. doi: 10.1186/s13046-019-1317-6. J Exp Clin Cancer Res. 2019. PMID: 31319863 Free PMC article.
HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
Roca MS, Moccia T, Iannelli F, Testa C, Vitagliano C, Minopoli M, Camerlingo R, De Riso G, De Cecio R, Bruzzese F, Conte M, Altucci L, Di Gennaro E, Avallone A, Leone A, Budillon A. Roca MS, et al. Among authors: de cecio r. J Exp Clin Cancer Res. 2022 Mar 3;41(1):83. doi: 10.1186/s13046-022-02295-4. J Exp Clin Cancer Res. 2022. PMID: 35241126 Free PMC article.
Correction to: HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
Roca MS, Moccia T, Iannelli F, Testa C, Vitagliano C, Minopoli M, Camerlingo R, De Riso G, De Cecio R, Bruzzese F, Conte M, Altucci L, Di Gennaro E, Avallone A, Leone A, Budillon A. Roca MS, et al. Among authors: de cecio r. J Exp Clin Cancer Res. 2022 Apr 11;41(1):138. doi: 10.1186/s13046-022-02324-2. J Exp Clin Cancer Res. 2022. PMID: 35410264 Free PMC article. No abstract available.
Targeting the EGFR T790M mutation in non-small-cell lung cancer.
Normanno N, Maiello MR, Chicchinelli N, Iannaccone A, Esposito C, De Cecio R, D'alessio A, De Luca A. Normanno N, et al. Among authors: de luca a, de cecio r. Expert Opin Ther Targets. 2017 Feb;21(2):159-165. doi: 10.1080/14728222.2017.1272582. Epub 2016 Dec 23. Expert Opin Ther Targets. 2017. PMID: 28002980 Review.
Lurbinectedin in small cell lung cancer.
Manzo A, Sforza V, Carillio G, Palumbo G, Montanino A, Sandomenico C, Costanzo R, Esposito G, Laudato F, Mercadante E, La Manna C, Muto P, Totaro G, De Cecio R, Picone C, Piccirillo MC, Pascarella G, Normanno N, Morabito A. Manzo A, et al. Among authors: de cecio r. Front Oncol. 2022 Aug 30;12:932105. doi: 10.3389/fonc.2022.932105. eCollection 2022. Front Oncol. 2022. PMID: 36110944 Free PMC article. Review.
49 results